Liraglutide Not Beneficial in Advanced Heart Failure

This article originally appeared here.
Share this content:
Liraglutide Not Beneficial in Advanced Heart Failure
Liraglutide Not Beneficial in Advanced Heart Failure

TUESDAY, Aug. 2, 2016 (HealthDay News) -- Liraglutide (Victoza) doesn't appear to improve heart function in patients with advanced heart failure, according to a study published in the Aug. 2 issue of the Journal of the American Medical Association.

Kenneth Margulies, M.D., a professor of medicine and research director of heart failure and transplantation at the University of Pennsylvania in Philadelphia, and colleagues randomly assigned 300 recently hospitalized advanced heart failure patients to daily injections of liraglutide or placebo. Over six months, the researchers looked for the number of patients who died, who were readmitted to the hospital for heart failure, or whose disease had stabilized.

Among the 271 patients who completed the study, liraglutide had no significant effect on any of the outcomes Margulies' team was looking for. Among those taking liraglutide, 12 percent died versus 11 percent of those receiving placebo. Forty-one percent of those taking liraglutide were rehospitalized for heart failure, compared with 34 percent of those receiving placebo. No difference was seen between the groups in measurements of heart function and disease stability, including heart structure and function, six-minute walking distance, and quality of life. And, when the researchers looked at those with and without diabetes, they didn't see any significant differences between the groups.

"Among patients recently hospitalized with heart failure and reduced left ventricular ejection fraction, the use of liraglutide did not lead to greater posthospitalization clinical stability," the authors write. "These findings do not support the use of liraglutide in this clinical situation."

Several authors disclosed financial ties to the pharmaceutical industry. Liraglutide and matching placebo injections were supplied by Novo Nordisk.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Extended-Release Naltrexone Promising for Opioid Dependence

Extended-Release Naltrexone Promising for Opioid Dependence

Lower use of heroin, other illicit opioids with extended-release naltrexone in superiority analysis

New Expert Consensus Pathway for Mitral Regurgitation

New Expert Consensus Pathway for Mitral Regurgitation

Etiology, mechanism, severity, indications for treatment should be assessed after MR is identified

Many Dermatology Guideline Authors Get Industry Payments

Many Dermatology Guideline Authors Get Industry Payments

22 of 40 guideline authors receiving payments did not accurately disclose industry relationships

is free, fast, and customized just for you!

Already a member?

Sign In Now »